Catalog No.
DHC27701
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a-kappa
Clonality
Monoclonal
Target
T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
8 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
OKT3, CAS: 140608-64-6
Clone ID
Muromonab
[Muromonab CD3], PMID: 15954439
[Muromonab CD3--the first monoclonal antibody used in humans], PMID: 7971509
Muromonab CD3. A review of its pharmacology and therapeutic potential, PMID: 2503348
Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection, PMID: 8861551
Muromonab-CD3 and antithymocyte globulin in renal transplantation, PMID: 9391693
Muromonab-CD3, PMID: 1908673
Muromonab-CD3-induced neurotoxicity: report of two siblings, one of whom had subsequent cyclosporin-induced neurotoxicity, PMID: 11732768
Pharmacologic immunosuppression, PMID: 14766378
Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review, PMID: 8638282
Ten years of Orthoclone OKT3 (muromonab-CD3): a review, PMID: 9188368
Muromonab-CD3 therapy for refractory rejections after liver transplantation: a single-center experience during two decades in Japan, PMID: 20458505
Platelet procoagulant activity induced in vivo by muromonab-CD3 infusion in uremic patients, PMID: 11755950
Induction immunosuppression, PMID: 16969280
OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient, PMID: 12131696
Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation, PMID: 16862164
Muromonab CD3 (Orthoclone OKT3), PMID: 8531248
Aseptic meningitis and muromonab-CD3 therapy, PMID: 1905440
Antibody-enabled small-molecule drug discovery, PMID: 22743979
Muromonab-CD3 for the successful treatment of early chronic rejection after pediatric liver transplantation: report of a case, PMID: 21431500
Anti-CD3 antibodies, PMID: 8461387
Anti-CD3 antibody MacroGenics Inc, PMID: 16625825
A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study, PMID: 16770243
[Muromonab CD3 (Orthoclone OKT3) for the prophylaxis of heart allograft rejection. Hemodynamics and respiratory tolerance], PMID: 8572388
Engineered CD3 antibodies for immunosuppression, PMID: 12930354
Anaphylactoid reaction to muromonab-CD3 in a pediatric renal transplant recipient, PMID: 10641983
Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment, PMID: 2502568
Falsely elevated plasma parathyroid hormone level mimicking tertiary hyperparathyroidism, PMID: 21247852
A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients, PMID: 10165313
Teplizumab therapy for type 1 diabetes, PMID: 20095914
Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3), PMID: 9270425
Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center, PMID: 15866669
Induction therapy in cardiac transplantation: when and why?, PMID: 17545007
Generalized seizures associated with the use of muromonab-CD3 in two patients after kidney transplantation, PMID: 9161654
Immunosuppressive drugs, PMID: 1282440
Immunosuppressive preconditioning or induction regimens : evidence to date, PMID: 16956302
Monoclonal and polyclonal antibodies: clinical aspects, PMID: 1916908
CD3-specific antibody-induced active tolerance: from bench to bedside, PMID: 12563296
[Immunosuppressive therapy in renal transplantation], PMID: 8411796
Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion, PMID: 19348913
Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release, PMID: 23701319
Canadian Cardiovascular Society Consensus Conference update on cardiac transplantation 2008: Executive Summary, PMID: 19340342
Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach, PMID: 31973200
Comment: muromonab CD3 aseptic meningitis, PMID: 2508335
Mechanisms of action and overview of OKT3, PMID: 8588230
Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala), PMID: 18817833
Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance, PMID: 16187942
Monoclonal antibodies in renal transplantation: a review, PMID: 1418316
Prophylactic use of OKT3 in liver transplantation. A review, PMID: 1914765
Humanized antibodies: enhancing therapeutic utility through antibody engineering, PMID: 8360588
For research use only. Not for human or drug use.
